Publications

2019

Finnerty BM, Moore MD, Verma A, Aronova A, Huang S, Edwards DP, et al. UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2019;26(4):411-423.
Gross MD, Awamlh BA, Shoag JE, Mauer E, Banerjee S, Margolis DJ, et al. Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions. BMJ Surg Interv Health Technol. 2019;1(1):e000010.
Davuluri M, Long B, Semple S, Villanueva-Siles E, Aboumohamed A. Primary Urethral Melanoma: A Case Report and Literature Review. Urology. 2019;126:1-4.
Hamid AA, Gray KP, Huang Y, Bowden M, Pomerantz M, Loda M, et al. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. Eur Urol Oncol. 2019;2(5):475-482.
Vlachostergios PJ, Geyer JT, Miller J, Kosloff R, Beltran H, Tagawa ST. Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis. J Oncol Pract. 2019;15(6):343-345.
Ivanidze J, Lum M, Pisapia D, Magge R, Ramakrishna R, Kovanlikaya I, et al. MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma. J Neuroimaging. 2019;29(3):357-363.
Geyer JT. Myeloid Neoplasms with Germline Predisposition. Pathobiology. 2019;86(1):53-61.
Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019;30 Suppl 8:viii16-viii22.
Chang R, Tosi U, Voronina J, Adeuyan O, Wu LY, Schweitzer ME, et al. Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy. Neurooncol Adv. 2019;1(1):vdz004.
Kyriakides K, Selkin G, Selkin B, Iwenofu H, Magro CM. Chronic Fibrosing Vasculitis in the Setting of Still Disease. J Clin Rheumatol. 2019;25(7):e127-e130.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700